Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Schwabl

Showing results (71-80 of 147) with videos related to

Pageof 15
Sort By:
Digestive Diseases and Sciences|June 19, 2019
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal HypertensionGeorg Semmler, Judith Stift, Bernhard Scheiner, et al.
Gastroenterology|March 18, 2014
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitisMattias Mandorfer, Simona Bota, Philipp Schwabl, et al.
AIDS (London, England)|January 14, 2016
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver diseaseMattias Mandorfer, Philipp Schwabl, Sebastian Steiner, et al.
Advances in Medical Sciences|March 10, 2022
Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertensionPhilipp Schwabl, Berit Anna Seeland, Florian Riedl, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 2, 2017
ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosisTheresa Bucsics, Sophie Hoffman, Johanna Grünberger, et al.
Scientific Reports|February 20, 2020
Bioimpedance spectroscopy for fluid status assessment in patients with decompensated liver cirrhosis: Implications for peritoneal dialysisElisabeth Schwaiger, Amrei Simon, Peter Wabel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 15, 2020
Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsyJudith Stift, Georg Semmler, Katharina Wöran, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2021
Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and DeathMathias Jachs, Lukas Hartl, Benedikt Simbrunner, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 4, 2024
Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonistGerardo M Castillo, Yao Yao, Rebecca E Guerra, et al.
Plos Genetics|December 16, 2020
Culture-free genome-wide locus sequence typing (GLST) provides new perspectives on Trypanosoma cruzi dispersal and infection complexityPhilipp Schwabl, Jalil Maiguashca Sánchez, Jaime A Costales, et al.
Pageof 15

Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
Digestive Diseases and Sciences|June 19, 2019
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal HypertensionGeorg Semmler, Judith Stift, Bernhard Scheiner, et al.
Gastroenterology|March 18, 2014
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitisMattias Mandorfer, Simona Bota, Philipp Schwabl, et al.
AIDS (London, England)|January 14, 2016
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver diseaseMattias Mandorfer, Philipp Schwabl, Sebastian Steiner, et al.
Advances in Medical Sciences|March 10, 2022
Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertensionPhilipp Schwabl, Berit Anna Seeland, Florian Riedl, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 2, 2017
ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosisTheresa Bucsics, Sophie Hoffman, Johanna Grünberger, et al.
Scientific Reports|February 20, 2020
Bioimpedance spectroscopy for fluid status assessment in patients with decompensated liver cirrhosis: Implications for peritoneal dialysisElisabeth Schwaiger, Amrei Simon, Peter Wabel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 15, 2020
Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsyJudith Stift, Georg Semmler, Katharina Wöran, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2021
Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and DeathMathias Jachs, Lukas Hartl, Benedikt Simbrunner, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 4, 2024
Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonistGerardo M Castillo, Yao Yao, Rebecca E Guerra, et al.
Plos Genetics|December 16, 2020
Culture-free genome-wide locus sequence typing (GLST) provides new perspectives on Trypanosoma cruzi dispersal and infection complexityPhilipp Schwabl, Jalil Maiguashca Sánchez, Jaime A Costales, et al.
Pageof 15